The effects of dopamine, haloperidol and bromocriptine on intraocular pressure
| ISSN: |
1573-2630
|
|---|---|
| Keywords: |
bromocriptine ; dopamine ; haloperidol ; intraocular pressure ; prolactin
|
| Source: |
Springer Online Journal Archives 1860-2000
|
| Topics: |
Medicine
|
| Notes: |
Abstract In a double-blind randomised, prospective single dose study, we measured intraocular pressure (IOP), pupil diameter, systemic blood pressure and heart rate in 43 ocular normotensive subjects before (baseline) and 2, 4, and 6 hours after topical instillation of the following drugs: dopamine 2% (n=11), a dopamine receptor blocking drug, haloperidol 0.5% (n=11), a dopamine receptor stimulating drug, bromocriptine 0.05% (n=11) and 0.1% (n=10). In the groups receiving dopamine or haloperidol, there were no significant differences in IOP compared with baseline values (p〉0.01). But, a significant decrease in IOP compared with the baseline values was found in both bromocriptine groups (p〈0.001). With the 0.05% and 0.1% concentrations, maximum reductions in intraocular pressure were 22.0%±5.8% and 28.4%±9.8%, respectively. No significant differences in mean pupil diameter, systemic blood pressure and heart rate were detected in all of these groups. In addition, in the group receiving bromocriptine 0.1%, there was no change in serum prolactin levels. These results suggest that topically administered bromocriptine has satisfactory intraocular pressure lowering capacity without serious ocular or systemic side effects. Consequently we conclude that, an ophthalmic formulation of bromocriptine may have substantial clinical potential for the treatment of glaucoma.
|
| Type of Medium: |
Electronic Resource
|
| URL: |
| _version_ | 1798296653854146560 |
|---|---|
| autor | Elibol, Orhan Güler, Cenap Yüksel, Nurşen |
| autorsonst | Elibol, Orhan Güler, Cenap Yüksel, Nurşen |
| book_url | http://dx.doi.org/10.1007/BF00917988 |
| datenlieferant | nat_lic_papers |
| hauptsatz | hsatz_simple |
| identnr | NLM194444449 |
| issn | 1573-2630 |
| journal_name | International ophthalmology |
| materialart | 1 |
| notes | Abstract In a double-blind randomised, prospective single dose study, we measured intraocular pressure (IOP), pupil diameter, systemic blood pressure and heart rate in 43 ocular normotensive subjects before (baseline) and 2, 4, and 6 hours after topical instillation of the following drugs: dopamine 2% (n=11), a dopamine receptor blocking drug, haloperidol 0.5% (n=11), a dopamine receptor stimulating drug, bromocriptine 0.05% (n=11) and 0.1% (n=10). In the groups receiving dopamine or haloperidol, there were no significant differences in IOP compared with baseline values (p〉0.01). But, a significant decrease in IOP compared with the baseline values was found in both bromocriptine groups (p〈0.001). With the 0.05% and 0.1% concentrations, maximum reductions in intraocular pressure were 22.0%±5.8% and 28.4%±9.8%, respectively. No significant differences in mean pupil diameter, systemic blood pressure and heart rate were detected in all of these groups. In addition, in the group receiving bromocriptine 0.1%, there was no change in serum prolactin levels. These results suggest that topically administered bromocriptine has satisfactory intraocular pressure lowering capacity without serious ocular or systemic side effects. Consequently we conclude that, an ophthalmic formulation of bromocriptine may have substantial clinical potential for the treatment of glaucoma. |
| package_name | Springer |
| publikationsjahr_anzeige | 1992 |
| publikationsjahr_facette | 1992 |
| publikationsjahr_intervall | 8009:1990-1994 |
| publikationsjahr_sort | 1992 |
| publisher | Springer |
| reference | 16 (1992), S. 343-347 |
| schlagwort | bromocriptine dopamine haloperidol intraocular pressure prolactin |
| search_space | articles |
| shingle_author_1 | Elibol, Orhan Güler, Cenap Yüksel, Nurşen |
| shingle_author_2 | Elibol, Orhan Güler, Cenap Yüksel, Nurşen |
| shingle_author_3 | Elibol, Orhan Güler, Cenap Yüksel, Nurşen |
| shingle_author_4 | Elibol, Orhan Güler, Cenap Yüksel, Nurşen |
| shingle_catch_all_1 | Elibol, Orhan Güler, Cenap Yüksel, Nurşen The effects of dopamine, haloperidol and bromocriptine on intraocular pressure bromocriptine dopamine haloperidol intraocular pressure prolactin bromocriptine dopamine haloperidol intraocular pressure prolactin Abstract In a double-blind randomised, prospective single dose study, we measured intraocular pressure (IOP), pupil diameter, systemic blood pressure and heart rate in 43 ocular normotensive subjects before (baseline) and 2, 4, and 6 hours after topical instillation of the following drugs: dopamine 2% (n=11), a dopamine receptor blocking drug, haloperidol 0.5% (n=11), a dopamine receptor stimulating drug, bromocriptine 0.05% (n=11) and 0.1% (n=10). In the groups receiving dopamine or haloperidol, there were no significant differences in IOP compared with baseline values (p〉0.01). But, a significant decrease in IOP compared with the baseline values was found in both bromocriptine groups (p〈0.001). With the 0.05% and 0.1% concentrations, maximum reductions in intraocular pressure were 22.0%±5.8% and 28.4%±9.8%, respectively. No significant differences in mean pupil diameter, systemic blood pressure and heart rate were detected in all of these groups. In addition, in the group receiving bromocriptine 0.1%, there was no change in serum prolactin levels. These results suggest that topically administered bromocriptine has satisfactory intraocular pressure lowering capacity without serious ocular or systemic side effects. Consequently we conclude that, an ophthalmic formulation of bromocriptine may have substantial clinical potential for the treatment of glaucoma. 1573-2630 15732630 Springer |
| shingle_catch_all_2 | Elibol, Orhan Güler, Cenap Yüksel, Nurşen The effects of dopamine, haloperidol and bromocriptine on intraocular pressure bromocriptine dopamine haloperidol intraocular pressure prolactin bromocriptine dopamine haloperidol intraocular pressure prolactin Abstract In a double-blind randomised, prospective single dose study, we measured intraocular pressure (IOP), pupil diameter, systemic blood pressure and heart rate in 43 ocular normotensive subjects before (baseline) and 2, 4, and 6 hours after topical instillation of the following drugs: dopamine 2% (n=11), a dopamine receptor blocking drug, haloperidol 0.5% (n=11), a dopamine receptor stimulating drug, bromocriptine 0.05% (n=11) and 0.1% (n=10). In the groups receiving dopamine or haloperidol, there were no significant differences in IOP compared with baseline values (p〉0.01). But, a significant decrease in IOP compared with the baseline values was found in both bromocriptine groups (p〈0.001). With the 0.05% and 0.1% concentrations, maximum reductions in intraocular pressure were 22.0%±5.8% and 28.4%±9.8%, respectively. No significant differences in mean pupil diameter, systemic blood pressure and heart rate were detected in all of these groups. In addition, in the group receiving bromocriptine 0.1%, there was no change in serum prolactin levels. These results suggest that topically administered bromocriptine has satisfactory intraocular pressure lowering capacity without serious ocular or systemic side effects. Consequently we conclude that, an ophthalmic formulation of bromocriptine may have substantial clinical potential for the treatment of glaucoma. 1573-2630 15732630 Springer |
| shingle_catch_all_3 | Elibol, Orhan Güler, Cenap Yüksel, Nurşen The effects of dopamine, haloperidol and bromocriptine on intraocular pressure bromocriptine dopamine haloperidol intraocular pressure prolactin bromocriptine dopamine haloperidol intraocular pressure prolactin Abstract In a double-blind randomised, prospective single dose study, we measured intraocular pressure (IOP), pupil diameter, systemic blood pressure and heart rate in 43 ocular normotensive subjects before (baseline) and 2, 4, and 6 hours after topical instillation of the following drugs: dopamine 2% (n=11), a dopamine receptor blocking drug, haloperidol 0.5% (n=11), a dopamine receptor stimulating drug, bromocriptine 0.05% (n=11) and 0.1% (n=10). In the groups receiving dopamine or haloperidol, there were no significant differences in IOP compared with baseline values (p〉0.01). But, a significant decrease in IOP compared with the baseline values was found in both bromocriptine groups (p〈0.001). With the 0.05% and 0.1% concentrations, maximum reductions in intraocular pressure were 22.0%±5.8% and 28.4%±9.8%, respectively. No significant differences in mean pupil diameter, systemic blood pressure and heart rate were detected in all of these groups. In addition, in the group receiving bromocriptine 0.1%, there was no change in serum prolactin levels. These results suggest that topically administered bromocriptine has satisfactory intraocular pressure lowering capacity without serious ocular or systemic side effects. Consequently we conclude that, an ophthalmic formulation of bromocriptine may have substantial clinical potential for the treatment of glaucoma. 1573-2630 15732630 Springer |
| shingle_catch_all_4 | Elibol, Orhan Güler, Cenap Yüksel, Nurşen The effects of dopamine, haloperidol and bromocriptine on intraocular pressure bromocriptine dopamine haloperidol intraocular pressure prolactin bromocriptine dopamine haloperidol intraocular pressure prolactin Abstract In a double-blind randomised, prospective single dose study, we measured intraocular pressure (IOP), pupil diameter, systemic blood pressure and heart rate in 43 ocular normotensive subjects before (baseline) and 2, 4, and 6 hours after topical instillation of the following drugs: dopamine 2% (n=11), a dopamine receptor blocking drug, haloperidol 0.5% (n=11), a dopamine receptor stimulating drug, bromocriptine 0.05% (n=11) and 0.1% (n=10). In the groups receiving dopamine or haloperidol, there were no significant differences in IOP compared with baseline values (p〉0.01). But, a significant decrease in IOP compared with the baseline values was found in both bromocriptine groups (p〈0.001). With the 0.05% and 0.1% concentrations, maximum reductions in intraocular pressure were 22.0%±5.8% and 28.4%±9.8%, respectively. No significant differences in mean pupil diameter, systemic blood pressure and heart rate were detected in all of these groups. In addition, in the group receiving bromocriptine 0.1%, there was no change in serum prolactin levels. These results suggest that topically administered bromocriptine has satisfactory intraocular pressure lowering capacity without serious ocular or systemic side effects. Consequently we conclude that, an ophthalmic formulation of bromocriptine may have substantial clinical potential for the treatment of glaucoma. 1573-2630 15732630 Springer |
| shingle_title_1 | The effects of dopamine, haloperidol and bromocriptine on intraocular pressure |
| shingle_title_2 | The effects of dopamine, haloperidol and bromocriptine on intraocular pressure |
| shingle_title_3 | The effects of dopamine, haloperidol and bromocriptine on intraocular pressure |
| shingle_title_4 | The effects of dopamine, haloperidol and bromocriptine on intraocular pressure |
| sigel_instance_filter | dkfz geomar wilbert ipn albert fhp |
| source_archive | Springer Online Journal Archives 1860-2000 |
| timestamp | 2024-05-06T09:55:31.938Z |
| titel | The effects of dopamine, haloperidol and bromocriptine on intraocular pressure |
| titel_suche | The effects of dopamine, haloperidol and bromocriptine on intraocular pressure |
| topic | WW-YZ |
| uid | nat_lic_papers_NLM194444449 |